The convergence of federal SMR permitting reform, NRC reviews at Palisades, and the broader nuclear-friendly policy environment under the Trump administration is accelerating demand for HALEU — the specialized fuel that most advanced reactor designs require. Centrus Energy LEU holds the only NRC license to produce HALEU in the United States, a position it reached with DOE funding.
Energy
Federal Nuclear Push Makes Centrus Energy's HALEU Monopoly More Valuable by the Month
As SMR developers line up for NRC approvals and DOE support, the only U.S. company licensed to enrich high-assay low-enriched uranium sits at the center of the entire supply chain.
1-YEAR MOVE
LEU
▼54.3%
| Ticker | Company | 1-year change |
|---|---|---|
| LEU | Centrus Energy | −54.3% |
Every advanced reactor that gets approved needs HALEU. Right now, in the United States, that means it needs Centrus.
Who cashes in: Centrus is the direct and unavoidable beneficiary. Every SMR developer that advances toward construction — Oklo, NuScale, TerraPower (private), X-energy (private) — needs HALEU, and there is currently no commercial-scale U.S. alternative to Centrus. The company's leverage to the nuclear buildout narrative is structural, not cyclical. As the federal government pushes to reduce dependence on Russian uranium enrichment (Russia's TENEX has historically been a major HALEU supplier), Centrus becomes a national security asset, not just a commercial one. Uranium Energy Corp UEC and Energy Fuels UUUU mine the uranium that eventually gets enriched — they benefit from rising demand but are one step removed from the HALEU bottleneck.
Who's exposed: The risk to Centrus is concentration: it has one facility, one product line, and one government customer relationship. Any DOE funding disruption or policy reversal hits the entire thesis. Centrus is also a small-cap with limited float, which means the stock can move violently on contract news in either direction. Russian enrichment capacity remains a competitive overhang — if sanctions on Russian nuclear fuel are relaxed, the urgency around domestic HALEU production diminishes.
Watch for DOE contract extensions or new HALEU purchase agreements — those are the revenue-confirming events. Also watch the NRC's Palisades SMR review timeline; faster approvals pull forward the date when HALEU demand becomes commercial rather than demonstration-scale.
Source: original report ↗
Free alerts
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.